PAVmed Inc.

PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.

อุตสาหกรรม

Medical - Devices

ภาคส่วน

Healthcare

สำนักงานใหญ่

US

ซีอีโอ

Lishan Aklog

จดทะเบียนตั้งแต่

27 ก.ค. 2559

พนักงาน

41